ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner

ANI Pharmaceuticals’ CEO Nikhil Lalwani Named EY Entrepreneur Of The Year® 2024 New Jersey Award Winner

Recognized for outstanding entrepreneurial leadership, driving impressive growth, and patient impact



PRINCETON, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that its Chief Executive Officer, Nikhil Lalwani, has been named an Ernst & Young LLP (EY US) Entrepreneur Of The Year® 2024 New Jersey Award winner. Entrepreneur Of The Year is the preeminent competitive awards program for entrepreneurs and leaders of high-growth companies.

Mr. Lalwani was selected by an independent judging panel made up of previous award winners, leading CEOs, and other business leaders. Candidates were evaluated based on their ability to create long-term value through entrepreneurial spirit, commitment to their purpose, and the demonstration of growth and substantial impact, among other key indicators.

Nikhil Lalwani, President and CEO of ANI, stated, “I am deeply humbled and honored to receive this prestigious award on behalf of the entire ANI Pharmaceuticals team. We remain steadfastly committed to our purpose: Serving Patients, Improving Lives. In parallel, we have achieved strong financial results, increasing our Enterprise Value approximately 2.8X since September 2020, when I joined as CEO. Each ANI team member and our Board has played an important role in driving our success. I share this honor with them and our customers, suppliers, partners, and shareholders whose support we count on and are so grateful for.”

As a New Jersey award winner, Mr. Lalwani is now eligible for consideration for the Entrepreneur Of The Year 2024 National Awards and for the World Entrepreneur Of The Year® Award in June 2025.

The Entrepreneur Of The Year program has recognized the leadership of entrepreneurs such as:

  • Howard Schultz of Starbucks Coffee Company
  • James Park of Fitbit
  • Jodi Berg of Vitamix
  • Hamdi Ulukaya of Chobani, Inc.
  • Reid Hoffman and Jeff Weiner of LinkedIn Corporation
  • Sheila Mikhail of AskBio
  • Michael Happe of Winnebago Industries

Entrepreneur Of the Year recognizes many different types of business leaders for their ingenuity, courage, and entrepreneurial spirit. The program celebrates original founders who bootstrapped their business from inception or who raised outside capital to grow their company; transformational CEOs who infused innovation into an existing organization to catapult its trajectory; and multigenerational family business leaders who reimagined a legacy business model to fortify it for the future.

In addition to Entrepreneur Of The Year, EY US supports other entrepreneurs through the  (Winning Women) program and the  (EAN) to help connect women founders and Black and Hispanic/Latino entrepreneurs, respectively, with the resources, network and access needed to unlock their full potential.

Sponsors

Founded and produced by Ernst & Young LLP, the Entrepreneur Of The Year Awards include presenting sponsors PNC Bank, Cresa, Marsh USA, SAP, and the Ewing Marion Kauffman Foundation. In New Jersey, sponsors also include DLA Piper and Empire Valuation Consultants.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. The Company is focused on delivering sustainable growth by scaling up its Rare Disease business through its lead asset Purified Cortrophin® Gel, strengthening its Generics business with enhanced research and development capabilities, delivering innovation in Established Brands, and leveraging its U.S. based manufacturing footprint. For more information, please visit our website .

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E:

Media Contact:

Faith Pomeroy-Ward

T: 817-807-8044

E:



EN
25/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

ANI Pharmaceuticals Inc: 1 director

A director at ANI Pharmaceuticals Inc sold 6,000 shares at 74.230USD and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 F...

ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenue...

 PRESS RELEASE

ANI Pharmaceuticals to Present at Upcoming Investor Conferences

ANI Pharmaceuticals to Present at Upcoming Investor Conferences PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Company’s executive leadership team, will present at the following investor conferences: Raymond James & Associates’ 47th Annual Institutional Investors Conference on Tuesday, March 3, 2026, at 7:30am ETLeerink Partners Global Healthcare Conference on Tuesday, March 10, 2026, at 3:00pm ETBarclays 28th Annual Globa...

 PRESS RELEASE

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Finan...

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 financial results on Friday, February 27, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to ...

 PRESS RELEASE

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 20...

ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228 million and $7.37 to $7.64, respectivelyRare Disease business delivered exceptional growth with full year 2025 Purified Cortrophin® Gel net revenues of $347.8 million, up 76% year-over-year, and ILUVIEN and YUTIQ net revenues of $74.9 million, based on preliminary, una...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch